3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tong Ren Tang Technologies Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -40.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
TGRNF's 3-Year ROIIC % is ranked worse than 82.61% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs TGRNF: -40.12
Tong Ren Tang Technologies Co (OTCPK:TGRNF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tong Ren Tang Technologies Co 3-Year ROIIC % Related Terms
Tong Ren Tang Technologies Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tong Ren Tang Technologies Co 3-Year ROIIC % Chart
TGRNF vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tong Ren Tang Technologies Co (TGRNF) has a 3-Year ROIIC % of -40.12 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tong Ren Tang Technologies Co and its competitors. According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #779 out of 943 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Tong Ren Tang Technologies Co's 3-Year ROIIC % too high?
Tong Ren Tang Technologies Co's current 3-Year ROIIC % is -40.12. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #779 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #779 out of 943 companies for 3-Year ROIIC %. This places Tong Ren Tang Technologies Co in the lower half of its industry. The industry median 3-Year ROIIC % is 3.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tong Ren Tang Technologies Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current 3-Year ROIIC % is -40.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co (TGRNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.84, compared to a current price of $0.49 — trading 41.1% below its estimated fair value. The current 3-Year ROIIC % is -40.12. Tong Ren Tang Technologies Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current 3-Year ROIIC % is -40.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 41.1% below its estimated GF Value™ of $0.84.
GuruFocus considers Tong Ren Tang Technologies Co to be Significantly Undervalued.
Key valuation signals for TGRNF:
3-Year ROIIC %: -40.12
GF Value™: $0.84 vs. price of $0.49 (41.1% below fair value)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Business Description
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
50GF Score
Get the complete analysis for TGRNF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
